prabotulinumtoxinA-xvfs
Commercial- Indications
- Glabellar lines
Company intelligence / Profile preview
Evolus, Inc.
Newport Beach, California, United Statesevolus.com ↗
- Ownership
- Public · EOLS
- Employees
- ~332
- Development stage
- Commercial
01
Overview
Evolus has a commercially available neurotoxin product Jeuveau® (prabotulinumtoxinA-xvfs) for temporary improvement of moderate to severe frown lines. The company recently announced positive topline results from a pivotal trial for its first two Evolysse™ dermal filler products and plans to submit Premarket Approval applications to the FDA within 90 days as of May 2024.
- Therapeutic areas
- Dermatology
- Modalities
- NeurotoxinsDermal Fillers
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Financials
- Market cap
- $448.8M
- Total revenue
- $297.2M
- Enterprise value
- $572.7M
Beyond the preview
Go deeper on Evolus, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evolus, Inc..